Temple University Health System

Criteria to predict cytokine storm in COVID-19 patients identified by Temple Researchers

Newswise — (Philadelphia, PA) - Like a cold front that moves in, setting the stage for severe weather, coronavirus infection triggers showers of infection-fighting immune molecules - showers that sometimes escalate into a chaotic immune response known as a cytokine storm. About 20 to 30 percent of patients hospitalized with COVID-19 develop severe immune manifestations, in some instances leading to cytokine storm, with life-threatening organ damage and high risk of death.

Predicting which COVID-19 patients will develop cytokine storm is challenging, owing to the many variables that influence immune function. But now, in breakthrough work, researchers at the Lewis Katz School of Medicine at Temple University (LKSOM) have developed and validated predictive criteria for early identification of COVID-19 patients who are developing hyperimmune responses, raising the possibility for early therapeutic intervention.

"If we can anticipate cytokine storm, we can apply treatment sooner and possibly decrease mortality," explained Roberto Caricchio, MD, Chief of the Section of Rheumatology, Director of the Temple Lupus Program, Professor of Medicine and Microbiology and Immunology at LKSOM, and lead author on the new report.

The report, published online in the Annals of the Rheumatic Diseases, is the first to identify criteria that can be readily used in clinical practice to potentially head off the worst of the hyperimmune attack against COVID-19.

The breakthrough is the result of an extensive collaboration between researchers and clinicians across multiple departments in the Lewis Katz School of Medicine and Temple University Hospital, constituting the Temple University COVID-19 Research Group.

According to Dr. Caricchio, large numbers of COVID-19 patients have been treated at Temple since the pandemic emerged in the United States. "We have a significant amount of data in terms of variables to predict cytokine storm," he said.

Since early March, every patient admitted to Temple University Hospital (TUH) has had data on more than 60 different laboratory variables collected daily until the time of recovery or time of death. Among variables measured every day are factors like white blood cell count, metabolic enzyme activity, and markers of inflammation and respiratory function. Importantly these markers are commonly used in hospitals across the globe and therefore are readily available.

The research group carried out statistical analyses on laboratory data for 513 COVID-19 patients hospitalized at TUH in March and April, 64 of whom developed cytokine storm. A genetic algorithm was used to identify cut-off values for each individual laboratory variable to define the predictive requirements for cytokine storm. Genetic algorithms mimic the processes of natural selection and evolution in analyzing the data, and in this case, over multiple iterations, the algorithm turned up variables indicating which patients are most likely to develop cytokine storm.

Overall, the analyses yielded six predictive criteria comprising three clusters of laboratory results relating to inflammation, cell death and tissue damage, and electrolyte imbalance. In particular, patients in cytokine storm exhibited a proinflammatory status and elevated levels of enzymes indicating significant systemic tissue damage. Moreover, patients who met the criteria had extended hospital stays and were at increased risk of death from COVID-19, with almost half of patients who experienced cytokine storm meeting all criteria within the first day of hospitalization.

The researchers validated the criteria in a subsequent cohort of 258 patients admitted to TUH for COVID-19 infection. "The algorithm correctly predicted cytokine storm in almost 70 percent of patients," Dr. Caricchio said.

"The ability to reproduce our results in a second cohort of patients means that our group of variables are effective criteria for cytokine storm diagnosis in COVID-19 patients," he added. The final step now is to have the criteria validated by other centers where COVID-19 patients are admitted for care.

Dr. Caricchio noted that the criteria could be applied to COVID-19 patients at any hospital or level of hospitalization anywhere in the world. "This makes the criteria very valuable for guiding decisions about how to treat COVID-19 patients worldwide," he said. Applied more broadly, the criteria could greatly facilitate early diagnosis and intervention, helping save many lives.

"This was a truly collective effort between frontline clinicians, researchers, and statisticians, and the results are one of the many testaments to the exceptional work Temple University and the Temple University Health System have performed," Dr. Caricchio concluded.

###

Other investigators who contributed to the new report include Lewis Katz School of Medicine and Temple University Hospital researchers and clinicians Chandra Dass, Clinical Radiology; Xinyan Zhang, Departments of Medicine and Rheumatology; Stefania Gallucci, Department of Microbiology and Immunology; David Fleece, Clinical Pediatrics; Michael Bromberg, Department of Medicine and Section of Hematology; and Gerard J. Criner, Department of Thoracic Medicine and Surgery. Statistical expertise was provided by Marcello Gallucci, Department of Psychology, University of Milano-Bicocca, Milan, Italy.

The research was supported in part by National Institutes of Health grant R56 AR072115-01 and the Lupus Research Alliance.

About Temple Health

Temple University Health System (TUHS) is a $2.2 billion academic health system dedicated to providing access to quality patient care and supporting excellence in medical education and research. The Health System consists of Temple University Hospital (TUH); TUH-Episcopal Campus; TUH-Jeanes Campus; TUH-Northeastern Campus; The Hospital of Fox Chase Cancer Center and Affiliates, an NCI-designated comprehensive cancer center; Temple Transport Team, a ground and air-ambulance company; Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices; and Temple Faculty Practice Plan, Inc., TUHS's physician practice plan comprised of more than 500 full-time and part-time academic physicians in 20 clinical departments. TUHS is affiliated with the Lewis Katz School of Medicine at Temple University.

Temple Health refers to the health, education and research activities carried out by the affiliates of Temple University Health System (TUHS) and by the Katz School of Medicine. TUHS neither provides nor controls the provision of health care. All health care is provided by its member organizations or independent health care providers affiliated with TUHS member organizations. Each TUHS member organization is owned and operated pursuant to its governing documents.

It is the policy of Temple University Health System that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 4179
Released: 2-Dec-2020 7:40 AM EST
No country ‘immune’ to COVID-19 economic shock, but Asian nations will bounce back faster
University of Cambridge

Study uses forty years of quarterly data to project a lengthy global recession from COVID-19 – knocking 3% off world GDP by end of next year. The manufacturing bases of China and East Asia are predicted to fare better than most Western economies.

Released: 1-Dec-2020 7:10 PM EST
American College of Surgeons calls on Congress to prevent CMS Medicare Physician Fee Schedule from taking effect
American College of Surgeons (ACS)

The Medicare Physician Fee Schedule released today by the Centers for Medicare & Medicaid Services (CMS) will harm patients and further destabilize a health care system already under severe strain from the COVID-19 pandemic.

Newswise: UNLV Immunologist on the Differences Between Two Leading COVID-19 Vaccine Candidates
Released: 1-Dec-2020 5:05 PM EST
UNLV Immunologist on the Differences Between Two Leading COVID-19 Vaccine Candidates
University of Nevada, Las Vegas (UNLV)

Millions around the world have waited for news about a COVID-19 vaccine, regarding it as the beginning of the end for the global pandemic and a herald for the eventual return to “normal life.” Recent announcements from pharmaceutical companies Pfizer and Moderna that their respective late-stage vaccine trials have shown a 90% or better effectiveness rate have received international applause, excitement furthered with estimates that doses could be ready as early as December.

Newswise: Why Older Adults Should Shop from Home While the Pandemic is Surging
Released: 1-Dec-2020 4:50 PM EST
Why Older Adults Should Shop from Home While the Pandemic is Surging
Rutgers University-New Brunswick

Leslie M. Kantor, professor and chair of the Department of Urban-Global Public Health at the Rutgers School of Public Health, talks about the new data from Public Health England, the country’s national health service, and explains why even the most independent seniors should avoid grocery shopping at this stage of the pandemic and how to use technology and help from family and friends.

Released: 1-Dec-2020 4:05 PM EST
Primary Care in a Pandemic: Spotting Mental Health Needs and More
Michigan Medicine - University of Michigan

The number of people dealing with mental distress caused by enduring months of pandemic, economic disruption and political turmoil is rising fast. And America’s primary care clinics are the front line for many of those mental health concerns. A new online toolkit aims to help primary care clinics cope with this influx, and draw from the expertise of mental health specialists and researchers.

Released: 1-Dec-2020 3:50 PM EST
New Study Finds Possible Link Between Sight-Threatening Eye Infection and Coronavirus
American Academy of Ophthalmology (AAO)

Researchers are warning of a possible link between a rare and devastating eye infection and COVID-19.

Released: 1-Dec-2020 2:40 PM EST
The claim that COVID-19 vaccines will cause more severe disease through antibody-dependent enhancement is not yet supported
Newswise

ADE has not been shown to occur in individuals that received COVID-19 vaccines to date.

Newswise: Supercomputers Help Model Potential SARS-CoV2 Protease Inhibitors for COVID-19
Released: 1-Dec-2020 1:55 PM EST
Supercomputers Help Model Potential SARS-CoV2 Protease Inhibitors for COVID-19
University of California San Diego

A team of researchers recently created a pharmacophore model and conducted data mining of the database of drugs approved by the U.S. Federal Drug Administration (FDA) to find potential inhibitors of papain-like protease of SARS-CoV2, one of the main viral proteins responsible for COVID-19.


Showing results

110 of 4179

close
1.34924